Long-Term Ibuprofen, Aspirin Use Linked To Lower Alzheimer’s Risk

The Authors of this Study Note That Inflammation May Be a Critical Piece in the Development of Dementia. Nsaids Help with Inflammation and May Affect Dementia Risk. This Study Sought To Understand More About The Long-Trm Impact of Nsaids On Dementia Risk.

Researchers used data from participants in the Rotterdam Study, A Current Prospective Population-Based Study in the Netherlands.

For the Current Analysis, Rebecchers Included participants Who Did Not Have Baseline Dementia, Including 11,745 Participants in the Final Analysis Based on All Their Criteria. The Average Age of Participants Was Around 66 Years Old.

Researchers used pharmacy records to examine participants’ oral nsaid use. They also divided nsaids into two categories: beta -myloid-42-lowering or non-beta-andamyloid-42-lowering.

This distinction had to do with prior data on how certain nsaids may affection Amyloid Levels in the brain. ACCUMULATION OF BETA-AMYLOID IN THE BRAIN IS RELATED TO INCREASED DEMINIA RISK.

Participants Underwent regular Dementia Screening. Refrachers Also Had Data On Several Health Indicators and Lifestyle Factors, Including Blood Pressure, Diabetes, Cholesterol Levels, Body Mass Index, Education Level, and Smoking Habs.

Refracchers Divideted NSAID USE INTO FOUR Main Categories:

1. Do not use
2. short-term use, which was less than 1 months
3. INTERMEDIATE-TERM USE, WHICH WAS 1 months to 2 years
4. Long-Term Use, Which Was More than 2 Years.

ADDITIONAL ANALYSES USED OTHER TIME FRAMES TO ALLOW FOR MORE ASSESMENT. Researchers used FEW Different Models to look at the relationship Between All-Cause Dementia and Time of Nsaid Use and To Account for Different Factors.

They Further driving severe sensitivity analyzes, Such as looking at the relationship between nsaids and Alzheimer’s Disease, and the association Between Dementia and Salicylates, substances Found in Medications Such As Aspirin.

Had an average folow-up time with participants of 14.5 Years. During the Follow-Up, 81.3% of participants used nsaids.

Just Under 6% of participants used only nsaids that did not have beta-andoid-42-lowering properties, and about 46% used combination of non-beet-friend-andoid-42-lowering and beta -myloid-42-lowering nsaids.

A Little Over 2,000 Participants Developed Dementia.

Short-term and intermediate-term use of nsaids slightly increased the risk for all-cause dementia, While long-term nsaid uses decite the risk.

The Association Between Long-Term Nsaid Use and Reded Risk for Alzheimer’s Disease was Stronger than for All-Cause Dementia.

They Also Found That Non-Beta-Ramyloid-42-Lowing Nsaids Appeared To Lower The Risk for All-Cause Dementia More than Beta-andyloid-42-Lowering nsaids.

Did not find an association Between cumulative nsaid dose and dementia risk reduction. They Also Found That Nsaids Did Not Appear To Lower The Risk for All-Cause Dementia Among Participants Who Had The APOE-E4 Allele.

The APOE-E4 Allele Is a Form of Gene, and Having It Can increased to Person’s Risk for Alzheimer’s Disease.

Vernon Williams, MD, A Sports Neurologist and Founding Director of the Center for Sports Neurology and Pain Medicine At Cedars-Sinai Orthopedics in Los Angeles, Who Was Not Involved in This Research, Commented With His Thoughts On The Study To Medical News Today.

HE TOLED US:

“I Think it’s very interest in that it is annother pione of evidence that Will Hopefully contributes to our Understanding of Dementia and Opportunities to reduce Risk. There are submitations to an observational study like This, but overall, it sems to be in line with other evidence and past studies that suggest inflammmation as having to Key Role in neurodegeneration (…) it further contributes to the understunding of chronic inflammmation as a target for target for target ADDITIONAL STUDY AND INTERVENTION. “

This Study Does Have Sub Subs Limitations. This Study Only included individuals from the netherlands, and must participants were White, so the results cannot be generalized to all People.

There was Missing Data for Participants, and Sub Information, Such as Alcohol Use, was self-repaired. The Study Also Cannot Establish Cause.

This Study was Also Able to Only Look at Prescription Use of Nsaids, Even Though Nsaids Are Also Available Over The Counter. It’s possible that subm participants Who Researchers Note Not To Be Taking Nsaids Were Doing So.

When it came to the diagnosis of Alzheimer’s, Could Not include biomarkers, so misclassification is positive. It is also possessible that participants who used nsaids long-term were Healthier than participants who only used nsaids in the short term.

DID ACCOUND REFOTCHERS FOR THE USE OF ASPIRIN IN ONE OF THE MODELS. They Did not categorize aspirin as an nsaid. WHEN ANALYZING ASPIRIN SEPARATELY, They Did Not Find An Association Between Long-Term Use and Reduced Dementia Risk.

The Authors Note That with the Slight increased in risk for all-cause dementia from short-term and intermediate-term use, The “Effect Estimates Were Too Small to Obtain Clinical Relay.”

Furthermore, The Researchers Also Acknowledge that looking at all-cause Dementia Includes Dementia Subtypes where nsaids may have no impact. Thus, if they are subtypes are included in the analysis, it is positive to have weakened effect estimates.

Finally, it is also possessible that Did Not Account for Celerin Release Factors Or participants were not taking prescribed medication.

Speaking to MNTStudy Author Mohammad Arfan Ikram, MD, PHD, Professor of Epidemiology at The Erasmus University Medical Center in the Netherlands, Further Noteral Several Limitations of Their Work:

“ In Other Words, There is a Reason Why these Did versus Did Not Take Nsaids. You are reasons may include arthritis, Pain, or other inflammatory conditions. It is impossible in Such Studies to Fully Adjust for the Effect of these other conditions. If they like other conditions are in any way linked to dementia, It May Than distort our findings. “

Overall, This Research Highlights A Potential Benefit of Nsaid Use in the Long Term. This Research Could Also Help with Creating Therapeutics That Protect Against Dementia.

Williams Note That “The Study Suggests That Exposure to Anti-Inflammatories Over Time May Be of Potential Benefit.”

“However,” I have cautious, “There are potential side efforts and riss Associated with Currently Available nsaids. The Findings That The Association was Stronger for Non-Amyloid Lowering Nsaids Combase To Those With Known Amyloid Lowering Properties is Interesting in that it implies the mechanism of action may not be entirely related to amyloid reduction. So other anti-inflammatory pathways and/or genertic risk factor efforts may be contribution to the benefits. “

More Research is Likely Needed Before there are Major Changes to Clinical Recommendations. The Study Itself Also Notes That May Be Inapprocelate for Older Adults to Use Nsaids.

Ikram Note:

“Our Findings Alone Are Instatient To Start Advishing People to Take Nsaids Formentia. Further Evidence from similar Studies or (randomized controlled trials) is Needed, complement with proper risk-benefit analyzes and also to Proper Assessment How Any Use of Nsaids May Or May Not Outweight Side-Effects or Impact On Other Bodily Functions. ”